Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 20/20 | 0.47 |
| ▸ | F3 | P13726 | 20/20 | 0.47 |
| ▸ | F2 | P00734 | 15/20 | 0.47 |
| ▸ | F10 | P00742 | 15/20 | 0.47 |
| ▸ | F11 | P03951 | 12/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5004015 | 0.93 | F7 (0.45) | F7F3F2F10F11 | |
| SCHEMBL4999804 | 0.91 | F7 (0.47) | F7F3F2F10F11 | |
| SCHEMBL5002965 | 0.90 | F7 (0.50) | F7F3F2F10F11 | |
| SCHEMBL5003007 | 0.90 | F7 (0.48) | F7F3F2F10F11 | |
| SCHEMBL5009078 | 0.89 | F7 (0.47) | F7F3F2F10F11 | |
| SCHEMBL5003420 | 0.89 | F7 (0.49) | F7F3F2F10F11 | |
| SCHEMBL5006885 | 0.89 | F7 (0.47) | F7F3F2F10F11 | |
| SCHEMBL5009014 | 0.88 | F7 (0.47) | F7F3F2F10F11 | |
| SCHEMBL4999327 | 0.88 | F7 (0.48) | F7F3F2F10F11 | |
| SCHEMBL5003067 | 0.87 | F7 (0.48) | F7F3F2F10F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | F7 3/4885F3 10/4885F2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.